125 related articles for article (PubMed ID: 16723171)
21. [EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)].
Cortot AB
Rev Pneumol Clin; 2010 Dec; 66(6):367-74. PubMed ID: 21167447
[TBL] [Abstract][Full Text] [Related]
22. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
Omuro AM; Kris MG; Miller VA; Franceschi E; Shah N; Milton DT; Abrey LE
Cancer; 2005 Jun; 103(11):2344-8. PubMed ID: 15844174
[TBL] [Abstract][Full Text] [Related]
23. [Prolonged survival of gefitinib treatment in patients with advanced and previously treated non-small cell lung cancer].
Nishikawa M; Kusano N; Yoshimoto N; Ito M; Kakemizu N; Nozaki M; Fujiwara M; Momiyama M; Kido Y
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1437-40. PubMed ID: 17033233
[TBL] [Abstract][Full Text] [Related]
24. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
[TBL] [Abstract][Full Text] [Related]
25. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.
Wong AS; Soong R; Seah SB; Lim SW; Chuah KL; Nga ME; Chin TM; Soo RA
J Thorac Oncol; 2008 Apr; 3(4):400-4. PubMed ID: 18379359
[TBL] [Abstract][Full Text] [Related]
26. Biomarkers of response to gefitinib in non-small-cell lung cancer.
Carbone DP
Nat Clin Pract Oncol; 2004 Dec; 1(2):66-7. PubMed ID: 16264818
[No Abstract] [Full Text] [Related]
27. Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras.
Kim HS; Park K; Jun HJ; Yi SY; Lee J; Ahn JS; Park YH; Kim S; Lee S; Ahn MJ
Oncology; 2009; 76(4):239-46. PubMed ID: 19246948
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
Lee VW; Schwander B; Lee VH
Hong Kong Med J; 2014 Jun; 20(3):178-86. PubMed ID: 24281768
[TBL] [Abstract][Full Text] [Related]
29. Gefitinib. Still no convincing results in non-small cell lung cancer.
Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034
[No Abstract] [Full Text] [Related]
30. Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer.
Yang RF; Yu B; Zhang RQ; Wang XH; Li C; Wang P; Zhang Y; Han B; Gao XX; Zhang L; Jiang ZM
Braz J Med Biol Res; 2017 Nov; 51(1):e6073. PubMed ID: 29185589
[TBL] [Abstract][Full Text] [Related]
31. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
32. Gefitinib plus docetaxel in non-small-cell lung cancer.
Singh N; Aggarwal AN
Lancet; 2009 Feb; 373(9663):541-2; author reply 542. PubMed ID: 19217980
[No Abstract] [Full Text] [Related]
33. Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.
DeGrendele H
Clin Lung Cancer; 2003 Sep; 5(2):83-5. PubMed ID: 14596689
[No Abstract] [Full Text] [Related]
34. EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer.
Sasaki H; Endo K; Mizuno K; Yano M; Fukai I; Yamakawa Y; Fujii Y
Lung Cancer; 2006 Jan; 51(1):135-6. PubMed ID: 16314000
[No Abstract] [Full Text] [Related]
35. Predictors of clinical response of non-small cell cancer to gefitinib.
Ardizzoni A; Tiseo M
JAMA; 2004 Apr; 291(13):1563; author reply 1563-4. PubMed ID: 15069041
[No Abstract] [Full Text] [Related]
36. Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.
Popat S; Barbachano Y; Ashley S; Norton A; O'Brien M
Lung Cancer; 2008 Feb; 59(2):227-31. PubMed ID: 17920156
[TBL] [Abstract][Full Text] [Related]
37. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.
Oh IJ; Ban HJ; Kim KS; Kim YC
Lung Cancer; 2012 Jul; 77(1):121-7. PubMed ID: 22333554
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
[TBL] [Abstract][Full Text] [Related]
39. Gefitinib and non-small cell lunt cancer.
Prescrire Int; 2013 Nov; 22(143):261-2. PubMed ID: 24427833
[TBL] [Abstract][Full Text] [Related]
40. Gefitinib ('Iressa', ZD1839) is active against brain metastases in a 77 year old patient.
Roggero E; Busi G; Palumbo A; Pedrazzini A
J Neurooncol; 2005 Feb; 71(3):277-80. PubMed ID: 15735917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
